How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,209 results for

Psychosis in Dementia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia

Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE ON THE USE OF Antipsychotics TO Treat Agitation OR Psychosis IN Patients WITH Dementia Guideline Writing Group Victor I. Reus, M.D., Chair Laura J. Fochtmann, M.D., M.B.I., Vice-Chair A. Evan Eyler, M.D., M.P .H. Donald M. Hilty, M.D. Marcela Horvitz-Lennon, M.D., M.P .H. Michael D. Jibson, Ph.D., M.D. Oscar L. Lopez, M.D. Jane Mahoney, Ph.D., R.N., PMHCNS-BC (...) of agitation or psychosis in individuals with dementia. Results of this expert survey are included in Appendix B of the practice guideline. Rating the Strength of Research Evidence and Recommendations The guideline recommendations are rated using GRADE (Grading of Recommendations Assessment, Development and Evaluation), which is used by multiple professional organizations around the world to develop practice guideline recommendations (Guyatt et al. 2013). With the GRADE ap- proach, the strength

2016 American Psychiatric Association

2. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia [Cochrane protocol]

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

3. Dementia: assessment, management and support for people living with dementia and their carers

burden (for example, the Anticholinergic Cognitive Burden Scale), but there is insufficient evidence to recommend one over the others. 1.6.4 For guidance on carrying out medication reviews, see medication review in the NICE guideline on medicines optimisation. 1.7 Managing non-cognitive symptoms Agitation, aggression, distress and psy Agitation, aggression, distress and psychosis chosis 1.7.1 Before starting non-pharmacological or pharmacological treatment for distress in people living with dementia (...) Dementia: assessment, management and support for people living with dementia and their carers Dementia: assessment, management and Dementia: assessment, management and support for people living with dementia support for people living with dementia and their carers and their carers NICE guideline Published: 20 June 2018 nice.org.uk/guidance/ng97 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

4. Psychosis symptoms in nursing home residents with and without dementia - cross-sectional analyses from the COSMOS study. (PubMed)

Psychosis symptoms in nursing home residents with and without dementia - cross-sectional analyses from the COSMOS study. To investigate the characteristics of nursing home residents with psychosis and the association with potential underlying factors, such as pain, sleep disturbances, and antipsychotic medication.Five hundred forty-five residents with and without dementia from 67 Norwegian nursing home units were included in the cross-sectional analyses. Psychosis was the main outcome measure (...) in our study; other outcome measures include quality of life (QoL), activities of daily living (ADL) function, cognitive function, pain, and antipsychotic medication.One hundred twelve residents had one or more symptoms of psychosis, and compared with residents without psychosis, they had lower QoL (p < 0.001), ADL function (p = 0.003), and cognitive functioning (p = 0.001). Adjusted logistic regression analyses showed that psychosis was associated with the prevalence of pain (OR: 3.19; 95% CI, 1.94

2019 International Journal of Geriatric Psychiatry

5. Developmental delay, treatment-resistant psychosis, and early-onset dementia in a man with 22q11 deletion syndrome and Huntington’s Disease (PubMed)

Developmental delay, treatment-resistant psychosis, and early-onset dementia in a man with 22q11 deletion syndrome and Huntington’s Disease 29712475 2018 12 07 1535-7228 175 5 2018 05 01 The American journal of psychiatry Am J Psychiatry Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntington's Disease. 400-407 10.1176/appi.ajp.2017.17060638 Farrell Martilias M From the Departments of Genetics and Psychiatry, University

Full Text available with Trip Pro

2018 The American Journal of Psychiatry

6. Antidepressants for agitation and psychosis in dementia. (PubMed)

Antidepressants for agitation and psychosis in dementia. Agitation and psychosis are common among older adults with dementia and are challenging to manage. At the present time, little is known about the efficacy and safety of antidepressant medications when used to treat these symptoms.To assess the safety and efficacy of antidepressants in treating psychosis and agitation in older adults with Alzheimer's disease, vascular, or mixed dementia.We searched the Cochrane Dementia and Cognitive (...) or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia.Two authors independently assessed trial quality and extracted trial data. We collected information on efficacy as measured by dementia neuropsychiatric symptom rating scales and adverse effects. Study authors were contacted for additional information.Nine trials including a total of 692 individuals were included

2011 Cochrane

7. A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03044249 Recruitment Status : Recruiting First Posted : February 6, 2017 Last Update Posted

2017 Clinical Trials

8. Distress Associated with Dementia-Related Psychosis and Agitation in Relation to Healthcare Utilization and Costs. (PubMed)

Distress Associated with Dementia-Related Psychosis and Agitation in Relation to Healthcare Utilization and Costs. Explore the relationship between behavioral and psychological symptoms of dementia (BPSD; specifically, delusions, hallucinations, and agitation/aggression) and associated caregiver distress with emergency department (ED) utilization, inpatient hospitalization, and expenditures for direct medical care.Retrospective cross-sectional cohort of participants with dementia (N = 332 (...) ) and informants from the Aging, Demographics, and Memory Study, a nationally representative survey of U.S. adults >70 years old.BPSD of interest and associated informant distress (trichotomized as none/low/high) were assessed using the Neuropsychiatric Inventory (NPI). Outcomes were determined from one year of Medicare claims and examined according to presence of BPSD and associated informant distress, adjusting for participant demographics, dementia severity, and comorbidity.Fifty-eight (15%) participants

Full Text available with Trip Pro

2017 The American Journal of Geriatric Psychiatry

9. Serotonin Reuptake Inhibitors for the Treatment of Coexisting Depression and Psychosis in Dementia of the Alzheimer Type. (PubMed)

Serotonin Reuptake Inhibitors for the Treatment of Coexisting Depression and Psychosis in Dementia of the Alzheimer Type. Four patients, ages 75 to 92 years, with a dementia of the Alzheimer type, presented with accompanying depression and psychosis. In these patients, treatment with a selective serotonin reuptake inhibitor resulted in a dramatic clearing of not only the depressive symptoms but the psychosis as well. Treatment was well tolerated in all cases.Copyright © 1994 American

2017 The American Journal of Geriatric Psychiatry

10. Affective Disorders, Psychosis and Dementia in a Community Sample of Older Men with and without Parkinson's Disease. (PubMed)

Affective Disorders, Psychosis and Dementia in a Community Sample of Older Men with and without Parkinson's Disease. Dementia and affective and psychotic symptoms are commonly associated with Parkinson's disease, but information about their prevalence and incidence in community representative samples remains sparse.We recruited a community-representative sample 38173 older men aged 65-85 years in 1996 and used data linkage to ascertain the presence of PD, affective disorders, psychotic (...) disorders and dementia. Diagnoses followed the International Classification of Disease coding system. Age was recorded in years. Follow up data were available until December 2011.The mean age of participants was 72.5 years and 333 men (0.9%) had PD at study entry. Affective and psychotic disorders and dementia were more frequent in men with than without PD (respective odds ratios: 6.3 [95%CI = 4.7, 8.4]; 14.2 [95%CI = 8.4, 24.0] and 18.2 [95%CI = 13.4, 24.6]). Incidence rate ratios of affective

Full Text available with Trip Pro

2016 PLoS ONE

11. Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Relapse (...) Prevention Study of Pimavanserin in Dementia-related Psychosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03325556 Recruitment Status : Recruiting First Posted : October 30, 2017 Last Update Posted : February 26, 2019 See

2017 Clinical Trials

12. Psychosis in behavioral variant frontotemporal dementia (PubMed)

Psychosis in behavioral variant frontotemporal dementia Dementia is generally characterized by cognitive impairment that can be accompanied by psychotic symptoms; for example, visual hallucinations are a core feature of dementia with Lewy bodies, and delusions are often seen in Alzheimer's disease. However, for behavioral variant of frontotemporal dementia (bvFTD), studies on the broad spectrum of psychotic symptoms are still lacking. The aim of this study was to systematically

Full Text available with Trip Pro

2017 Neuropsychiatric disease and treatment

13. Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice (PubMed)

Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice Policy interventions to address inappropriate prescribing of antipsychotic drugs to older people diagnosed with dementia are commonplace. In the UK, warnings were issued by the Medicines Healthcare products Regulatory Agency in 2004, 2009 and 2012 and the National Institute for Health and Care (...) Excellence guidance was published in 2006. It is important to evaluate the impact of such interventions.We analysed routinely collected primary-care data from 111,346 patients attending one of 689 general practices contributing to the Clinical Practice Research Datalink to describe the temporal changes in the prescribing of antipsychotic drugs to patients aged 65 years or over diagnosed with dementia without a concomitant psychosis diagnosis from 2001 to 2014 using an interrupted time series and a before

Full Text available with Trip Pro

2017 Drug Safety

14. De-escalation techniques for managing non-psychosis induced aggression in adults. (PubMed)

De-escalation techniques for managing non-psychosis induced aggression in adults. Aggression occurs frequently within health and social care settings. It can result in injury to patients and staff and can adversely affect staff performance and well-being. De-escalation is a widely used and recommended intervention for managing aggression, but the efficacy of the intervention as a whole and the specific techniques that comprise it are unclear.To assess the effects of de-escalation techniques (...) for managing non-psychosis-induced aggression in adults in care settings, in both staff and service users.We searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL and 14 other databases in September 2017, plus three trials registers in October 2017. We also checked references, and contacted study authors and authorities in the field to identify additional published and unpublished studies.We included randomised controlled trials (RCTs) and quasi-RCTs comparing de-escalation techniques with standard practice

2018 Cochrane

15. Assessment of psychosis

, gases, nitrites) Dextromethorphan Dementia Chronic thiamine deficiency (Korsakoff's psychosis) Acute hepatic porphyria Shared psychotic disorder (folie a deux) Organophosphate toxicity Anticholinergics Dopamine agonists Other prescription or over-the-counter medications Heavy metal toxicity Traumatic brain injury Brain tumour Epilepsy Multiple sclerosis Fahr's disease Encephalitis HIV Neurosyphilis Delirium with psychosis Vitamin B12 deficiency Folate deficiency Niacin deficiency Cushing's syndrome (...) Assessment of psychosis Assessment of psychosis - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of psychosis Last reviewed: February 2019 Last updated: June 2018 Summary Psychosis is a neurological syndrome associated with abnormal functioning of the frontal and temporal lobes and the dopaminergic projections to these areas. Symptoms develop when a threshold level of damage is reached or changes occur

2018 BMJ Best Practice

16. Acute Mental Status Change, Delirium, and New Onset Psychosis

Acute Mental Status Change, Delirium, and New Onset Psychosis New 2018 ACR Appropriateness Criteria ® 1 Acute Mental Status Change American College of Radiology ACR Appropriateness Criteria ® Acute Mental Status Change, Delirium, and New Onset Psychosis Variant 1: Acute mental status change. Increased risk for intracranial bleeding (ie, anticoagulant use, coagulopathy), hypertensive emergency, or clinical suspicion for intracranial infection, mass, or elevated intracranial pressure. Initial (...) Usually Not Appropriate ??? CT head with IV contrast Usually Not Appropriate ??? Variant 6: New onset psychosis. Initial imaging. Procedure Appropriateness Category Relative Radiation Level CT head without IV contrast May Be Appropriate ??? MRI head without and with IV contrast May Be Appropriate O MRI head without IV contrast May Be Appropriate O CT head without and with IV contrast Usually Not Appropriate ??? CT head with IV contrast Usually Not Appropriate ??? ACR Appropriateness Criteria ® 3 Acute

2019 American College of Radiology

17. The Interactive Relationship between Pain, Psychosis, and Agitation in People with Dementia: Results from a Cluster-Randomised Clinical Trial. (PubMed)

The Interactive Relationship between Pain, Psychosis, and Agitation in People with Dementia: Results from a Cluster-Randomised Clinical Trial. Background. Neuropsychiatric symptoms are common in people with dementia, and pain is thought to be an important underlying factor. Pain has previously been associated with agitation, and pain treatment has been shown to ameliorate agitated behaviour. So far, the association between pain and psychosis and the effect of pain treatment on psychotic (...) symptoms is unclear. Furthermore, the impact of opioid treatment on psychosis is not established. Aim. To investigate the efficacy of a stepwise protocol for treating pain (SPTP) on psychosis and agitation measured with the Neuropsychiatric Inventory, Nursing Home version, and to explore the impact of opioid analgesics on psychosis. Method. Secondary analyses are from a cluster-randomised controlled trial including 352 patients with advanced dementia and agitation from 18 nursing homes in Western

Full Text available with Trip Pro

2016 Behavioural neurology

18. Psychosis in Dementia

Psychosis in Dementia Psychosis in Dementia Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Psychosis in Dementia Psychosis (...) in Dementia Aka: Psychosis in Dementia , Dementia with Comorbid Psychosis From Related Chapters II. Epidemiology in : 50% III. Symptoms: Positive s Visual (most common) Phantom Border Syndrome Unseen person living in home s Patient believes items are being stolen Patient believes they must go to work Capgras' Syndrome Patient suspects care givers are imposters Thought disorders Incoherent Disorganized behavior IV. Symptoms: Negative Anhedonia Flat affect Apathy Social withdrawal V. Differential Diagnosis

2018 FP Notebook

19. The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion (PubMed)

The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion This present study aims to address the gap in the literature regarding the severity and underlying neural correlates of psychotic symptoms in frontotemporal dementia with and without the C9orf72 gene expansion.Fifty-six patients with behavioural variant frontotemporal dementia (20 with concomitant amyotrophic lateral sclerosis) and 23 healthy controls underwent (...) neuropsychological assessments, detailed clinical interview for assessment of psychosis symptoms, brain MRI and genetic testing. Carers underwent a clinical interview based upon the neuropsychiatric inventory. Patients were assessed at ForeFront, the Frontotemporal Dementia Research Group at Neuroscience Research Australia or at the Brain and Mind Centre, between January 2008 and December 2013. An index of psychosis was calculated, taking into account the degree and severity of psychosis in each case. Voxel

Full Text available with Trip Pro

2016 NeuroImage : Clinical

20. Symptoms of Anxiety in Older Adults with Depression, Dementia, or Psychosis: A Principal Component Analysis of the Geriatric Anxiety Inventory. (PubMed)

Symptoms of Anxiety in Older Adults with Depression, Dementia, or Psychosis: A Principal Component Analysis of the Geriatric Anxiety Inventory. The primary aim of this study was to examine anxiety symptoms as measured by the Geriatric Anxiety Inventory (GAI) in older patients with depression, dementia, or psychotic disorders. The secondary aim was to conduct a principal component analysis (PCA) of the GAI and to examine whether its subscales differ between the 3 disorders.We included data from

2016 Dementia and Geriatric Cognitive Disorders

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>